192 related articles for article (PubMed ID: 18854280)
1. [18F]fluorodeoxyglucose positron emission tomography in the management of lymphomas.
Kostakoglu L
Clin Lymphoma Myeloma; 2008 Oct; 8(5):273-6. PubMed ID: 18854280
[No Abstract] [Full Text] [Related]
2. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma.
Delbeke D; Stroobants S; de Kerviler E; Gisselbrecht C; Meignan M; Conti PS
Oncologist; 2009; 14 Suppl 2():30-40. PubMed ID: 19819922
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Lymphoma Therapy Using (18)F-FDG PET.
Lowe VJ; Wiseman GA
J Nucl Med; 2002 Aug; 43(8):1028-30. PubMed ID: 12163627
[No Abstract] [Full Text] [Related]
4. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma.
Cheson BD
Radiol Clin North Am; 2008 Mar; 46(2):213-23, vii. PubMed ID: 18619377
[TBL] [Abstract][Full Text] [Related]
5. Early restaging positron emission tomography with 18F-fluorodeoxyglucose in aggressive non-Hodgkin's lymphomas: is it too easy to be true?
Balzarotti M; Magagnoli M; Santoro A
Ann Oncol; 2003 Jul; 14(7):1155-6. PubMed ID: 12853364
[No Abstract] [Full Text] [Related]
6. Overview of early response assessment in lymphoma with FDG-PET.
MacManus MP; Seymour JF; Hicks RJ
Cancer Imaging; 2007; 7(1):10-8. PubMed ID: 17766210
[TBL] [Abstract][Full Text] [Related]
7. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET.
Altamirano J; Esparza JR; de la Garza Salazar J; Calvo PS; Vera SR; Chalapud Revelo JR; Estrada G
Arch Med Res; 2008 Jan; 39(1):69-77. PubMed ID: 18067998
[TBL] [Abstract][Full Text] [Related]
8. Change of initial staging at early remission evaluation with FDG-PET/CT in Hodgkin lymphoma: a report of two cases.
Molin D; Hagberg H; Suurküla M; Aström G
Acta Oncol; 2010 May; 49(4):526-8. PubMed ID: 20397779
[No Abstract] [Full Text] [Related]
9. Impact of bone marrow involvement on early positron emission tomography response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma.
Kreissl S; Voltin CA; Kaul H; Bühnen I; Mettler J; Pabst T; Eichenauer DA; Fuchs M; Diehl V; Dietlein M; Engert A; Borchmann P; Kobe C
Br J Haematol; 2022 Apr; 197(1):e5-e8. PubMed ID: 34929056
[No Abstract] [Full Text] [Related]
10. [Positron emission tomography (PET) in diagnosis and therapy planning of malignant lymphoma].
Dimitrakopoulou-Strauss A; Strauss LG; Goldschmidt H; Hegenbart U; Irngartinger G; Oberdorfer F; van Kaick G
Radiologe; 1997 Jan; 37(1):74-80. PubMed ID: 9157479
[TBL] [Abstract][Full Text] [Related]
11. Does interim 18F-FDG-PET response-adapted therapy really benefit advanced-stage Hodgkin lymphoma patients?
Adams HJ; Kwee TC
Nucl Med Commun; 2016 Dec; 37(12):1333-1334. PubMed ID: 27501435
[No Abstract] [Full Text] [Related]
12. Interpretation and validation of interim positron emission tomography in Hodgkin lymphoma.
Kobe C; Dietlein M; Fuchs M
Leuk Lymphoma; 2010 Mar; 51(3):552-3. PubMed ID: 20141443
[No Abstract] [Full Text] [Related]
13. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
Specht L
Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
[TBL] [Abstract][Full Text] [Related]
14. The use of positron emission tomography with [18F] 2-fluoro-D-2-deoxyglucose (FDG-PET) in Hodgkin and non-Hodgkin's lymphoma.
Chiusolo P; Sica S; Leone G
Hematology; 2003 Dec; 8(6):403-8. PubMed ID: 14668036
[TBL] [Abstract][Full Text] [Related]
15. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
Kostakoglu L; Coleman M; Leonard JP; Kuji I; Zoe H; Goldsmith SJ
J Nucl Med; 2002 Aug; 43(8):1018-27. PubMed ID: 12163626
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma.
Hernandez-Maraver D; Hernandez-Navarro F; Gomez-Leon N; Coya J; Rodriguez-Vigil B; Madero R; Pinilla I; Martin-Curto LM
Br J Haematol; 2006 Nov; 135(3):293-302. PubMed ID: 17032175
[TBL] [Abstract][Full Text] [Related]
17. False-positive FDG-PET findings due to bone metastasis from prostate cancer in staging of non-Hodgkin's lymphoma.
Inoue Y; Tamaki H; Yamagami T; Iwasaki H; Nakatsuka S; Soma T
Eur J Haematol; 2007 Jul; 79(1):88-90. PubMed ID: 17532762
[No Abstract] [Full Text] [Related]
18. Fluorine-18 fluorodeoxyglucose positron emission tomography for lymphoma: incorporating new technology into clinical care.
Kaplan LD
Am J Med; 2002 Mar; 112(4):320-1. PubMed ID: 11893374
[No Abstract] [Full Text] [Related]
19. 18F-FDG PET as a routine test for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: where is the evidence?
Juweid ME
J Nucl Med; 2008 Jan; 49(1):9-12. PubMed ID: 18077522
[No Abstract] [Full Text] [Related]
20. FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy?
Hutchings M
Hematol Oncol Clin North Am; 2014 Feb; 28(1):87-103. PubMed ID: 24287070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
